Background: The causal relationship between patent foramen ovale (PFO) and migraine with aura (MA) is controversial. We aimed at exploring whether attack clinical features relate to the presence of right-to-left shunt (RLS) in MA patients. Methods: We retrospectively examined a cohort of consecutive patients diagnosed with MA in our headache center and undergoing transcranial doppler (TCD) for RLS detection. We collected from our clinical electronic dossiers, clinical features of MA attacks (type, frequency, duration of aura phenomenon, trigger factors, onset age), family history for MA, thrombophilia genotypes, and the response to preventive treatments. RLS was stratified for severity according to the results of the TCD examination. Results: We found 111 patients. Binary logistic regression analysis showed that among features of MA attacks, only onset age was associated with the presence of RLS (p < 0.0001). Patients with RLS presented the first MA attack at a younger age (p < 0.0001). The greater RLS severity, the younger was onset age (p < 0.00001) and the presence of atrial septal aneurysms (ASA) was associated with a further decrease in onset age (ρ = –539, p < 0.00001). Family history for MA was associated with the presence of RLS (chi-square p = 0.022). Response to preventive treatments was not influenced by the type of treatment (antiplatelet compared with no antiplatelet drugs), comorbidity with migraine without aura, RLS presence, or by their double interactions (Logistic regression, consistently p > 0.05). Conclusion: Our findings support the hypothesis that although PFO does not influence MA attack frequency, it is not merely a bystander in MA physiopathology, as RLS, its severity, and the presence of ASA possibly make a difference in the disease history.

Keywords:
Migraine with aura, Right-to-left shunt, Migraine and stroke
1.
Takagi H, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of case-control studies of the association of migraine and patent foramen ovale.
J Cardiol
. 2016 Jun;67(6):493–503.
2.
Schwerzmann M, Nedeltchev K, Lagger F, Mattle HP, Windecker S, Meier B, et al. Prevalence and size of directly detected patent foramen ovale in migraine with aura.
Neurology
. 2005 Nov;65(9):1415–8.
3.
Kheiri B, Abdalla A, Osman M, Ahmed S, Hassan M, Bachuwa G, et al. Percutaneous Closure of Patent Foramen Ovale in Migraine: A Meta-Analysis of Randomized Clinical Trials.
JACC Cardiovasc Interv
. 2018 Apr;11(8):816–8.
4.
Anzola GP, Meneghetti G, Zanferrari C, Adami A, Dinia L, Del Sette M; SAM Study Group. Is migraine associated with right-to-left shunt a separate disease? Results of the SAM study.
Cephalalgia
. 2008 Apr;28(4):360–6.
5.
Domitrz I, Mieszkowski J, Kamińska A. Relationship between migraine and patent foramen ovale: a study of 121 patients with migraine.
Headache
. 2007 Oct;47(9):1311–8.
6.
Marchione P, Ghiotto N, Sances G, Guaschino E, Bosone D, Nappi G, et al. Clinical implications of patent foramen ovale in migraine with aura.
Funct Neurol
. 2008 Oct-Dec;23(4):201–5.
7.
Mitsikostas DD, Ashina M, Craven A, Diener HC, Goadsby PJ, Ferrari MD, et al.; EHF committee. European Headache Federation consensus on technical investigation for primary headache disorders.
J Headache Pain
. 2015;17(1):5.
8.
Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects.
BMJ Open
. 2018 Mar;8(3):e020498.
9.
West BH, Noureddin N, Mamzhi Y, Low CG, Coluzzi AC, Shih EJ, et al.: Frequency of Patent Foramen Ovale and Migraine in Patients With Cryptogenic Stroke. Stroke. 2018 May;49(5):1123–8.
10.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1–211.
11.
Evers S, Áfra J, Frese A, Goadsby PJ, Linde M, May A, et al.; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force.
Eur J Neurol
. 2009 Sep;16(9):968–81.
12.
Jauss M, Zanette E. Detection of right-to-left shunt with ultrasound contrast agent and transcranial Doppler sonography.
Cerebrovasc Dis
. 2000 Nov-Dec;10(6):490–6.
13.
Altamura C, Paolucci M, Brunelli N, Cascio Rizzo A, Vernieri F. Patent foramen ovale and migraine with aura in a retrospective analysis: age matters.
Neurol Sci
. 2018 Jun;39(S1 suppl 1):103–4.
14.
Quintana S, Genovese A, Rausa F, Manzoni GC, Torelli P. Migraine with typical aura: clinical features and their relationship with sex and age of onset. Results from the analysis of a large case series.
Neurol Sci
. 2018 Jun;39(S1 suppl 1):135–6.
15.
Sommer RJ, Nazif T, Privitera L, Robbins BT. Retrospective review of thienopyridine therapy in migraineurs with patent foramen ovale.
Neurology
. 2018 Nov;91(22):1002–9.
16.
Choi DY, Shin DH, Cho KH, Lee SP, Park S. Migraine with aura: a predictor of patent foramen ovale in children and adolescents.
Cephalalgia
. 2013 May;33(7):463–8.
17.
Elliott GC, Gurtu R, McCollum C, Newman WG, Wang T. Foramen ovale closure is a process of endothelial-to-mesenchymal transition leading to fibrosis.
PLoS One
. 2014 Sep;9(9):e107175.
18.
Zicari E, Tassi R, Stromillo ML, Pellegrini M, Bianchi S, Cevenini G, et al. Right-to-left shunt in CADASIL patients: prevalence and correlation with clinical and MRI findings.
Stroke
. 2008 Jul;39(7):2155–7.
19.
Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts.
Mayo Clin Proc
. 1984 Jan;59(1):17–20.
20.
Pristipino C, Sievert H, D’Ascenzo F, Louis Mas J, Meier B, Scacciatella P, et al.; Evidence Synthesis Team; Eapci Scientific Documents and Initiatives Committee; International Experts. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism.
Eur Heart J
. 2018, Epub ahead of print.
21.
Androulakis XM, Kodumuri N, Giamberardino LD, Rosamond WD, Gottesman RF, Yim E, et al. Ischemic stroke subtypes and migraine with visual aura in the ARIC study.
Neurology
. 2016 Dec;87(24):2527–32.
22.
Bayar N, Arslan Ş, Çağırcı G, Erkal Z, Üreyen ÇM, Çay S, et al. Assessment of morphology of patent foramen ovale with transesophageal echocardiography in symptomatic and asymptomatic patients.
J Stroke Cerebrovasc Dis
. 2015 Jun;24(6):1282–6.
23.
Mazzucco S, Li L, Binney L, Rothwell PM; Oxford Vascular Study Phenotyped Cohort. Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis.
Lancet Neurol
. 2018 Jul;17(7):609–17.
24.
Altamura C, Cascio Rizzo A, Maggio P, Viticchi G, Paolucci M, Brunelli N, et al. Prevalence and clinical profile of migraine with aura in a cohort of young patients with stroke: a preliminary retrospective analysis.
Neurol Sci
. 2019 May;40(S1 suppl 1):185–6.
25.
Dalkara T, Nozari A, Moskowitz MA. Migraine aura pathophysiology: the role of blood vessels and microembolisation. Lancet Neurol. 2010 Mar;9(3):309–17.
26.
Katsanos AH, Psaltopoulou T, Sergentanis TN, Frogoudaki A, Vrettou AR, Ikonomidis I, et al. Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia: A systematic review and diagnostic test accuracy meta-analysis.
Ann Neurol
. 2016 Apr;79(4):625–35.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.